M.D.C. (NYSE:MDC) issued its quarterly earnings data on Tuesday. The construction company reported $1.31 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.83 by $0.48, MarketWatch Earnings reports. The company had revenue of $886.80 million for the quarter, compared to analyst estimates of $806.74 million. M.D.C. had a return on equity of 14.75% and a net margin of 7.52%. The business’s quarterly revenue was up 21.0% compared to the same quarter last year. During the same quarter last year, the company posted $0.86 earnings per share.

Shares of NYSE MDC traded down $1.23 during midday trading on Friday, reaching $44.46. 41,574 shares of the company were exchanged, compared to its average volume of 527,802. The company has a current ratio of 7.53, a quick ratio of 1.85 and a debt-to-equity ratio of 0.63. M.D.C. has a 1 year low of $15.75 and a 1 year high of $48.99. The stock has a fifty day simple moving average of $36.51 and a 200 day simple moving average of $34.37. The stock has a market cap of $2.82 billion, a P/E ratio of 10.90, a PEG ratio of 8.28 and a beta of 1.54.

The business also recently declared a quarterly dividend, which will be paid on Wednesday, August 26th. Investors of record on Wednesday, August 12th will be issued a dividend of $0.33 per share. This represents a $1.32 dividend on an annualized basis and a dividend yield of 2.97%. The ex-dividend date of this dividend is Tuesday, August 11th. M.D.C.’s dividend payout ratio is currently 35.48%.

In related news, Director David Siegel sold 29,194 shares of the firm’s stock in a transaction dated Wednesday, July 29th. The shares were sold at an average price of $44.90, for a total value of $1,310,810.60. Following the completion of the sale, the director now owns 11,621 shares in the company, valued at $521,782.90. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, CEO Larry A. Mizel sold 110,224 shares of the firm’s stock in a transaction dated Wednesday, July 29th. The shares were sold at an average price of $44.82, for a total transaction of $4,940,239.68. Following the completion of the sale, the chief executive officer now owns 230,849 shares of the company’s stock, valued at approximately $10,346,652.18. The disclosure for this sale can be found here. Company insiders own 25.20% of the company’s stock.

Several brokerages have issued reports on MDC. JPMorgan Chase & Co. raised their price objective on M.D.C. from $38.50 to $50.00 and gave the stock a “neutral” rating in a report on Wednesday. Raymond James dropped their price objective on M.D.C. from $52.00 to $35.00 and set a “strong-buy” rating on the stock in a report on Thursday, April 9th. Evercore ISI raised M.D.C. from an “in-line” rating to an “outperform” rating and set a $61.00 price objective on the stock in a report on Wednesday. Wedbush dropped their price objective on M.D.C. from $40.00 to $29.00 and set a “neutral” rating on the stock in a report on Thursday, April 2nd. Finally, Zacks Investment Research raised M.D.C. from a “sell” rating to a “strong-buy” rating and set a $43.00 price objective on the stock in a report on Tuesday, July 14th. Two investment analysts have rated the stock with a sell rating, four have issued a hold rating, two have issued a buy rating and two have assigned a strong buy rating to the company’s stock. M.D.C. presently has a consensus rating of “Hold” and an average target price of $43.33.

M.D.C. Company Profile

M.DC Holdings, Inc, through its subsidiaries, engages in the homebuilding and financial service businesses. Its homebuilding operations include purchasing finished lots or developing lots for the construction and sale primarily of single-family detached homes to first-time and first-time move-up homebuyers under the Richmond American Homes name.

Further Reading: Average Daily Trade Volume – What You Need to Know

Earnings History for M.D.C. (NYSE:MDC)

Receive News & Ratings for M.D.C. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for M.D.C. and related companies with MarketBeat.com's FREE daily email newsletter.